Medical equipment is designed to aid in the diagnosis, monitoring or treatment of medical conditions. These devices are usually designed with rigorous safety standards. The medicalequipment is included in the category Medical technology.

(Market sharing) Dividing territories (also market division) is an agreement by two companies to stay out of each other's way and reduce competition in the agreed-upon territories. It is one of several anti-competitive practices outlawed in the United States.

The percentage of total sales represented by an individual manufacturer/importer, make or nameplate.

5 New Type CR2032 Energizer Batteries This is a new set of 5 type CR2032 Energizer batteries Brand New & Guaranteed Factory Fresh. The shelf life on Energizer batteries is 5 to 10 years These batteries are commonly required for Swatch, Fossil, Timex and Casio popular brands Energizer's reported failure rate is far less than 1/1000 of 1% This devotion to consistent quality has led it to control over 70% of market share in Switzerland, one of the world's leading watch producing countries Energizer is respected world wide for its uncompromising quality and consistent performance Energizer's technological leadership produces a variety of miniature batteries which are trusted for use by the best names in watch, computer, keyless entry, consumer electronics and hearing aid industries

78% (19)

George Chrch, visible man

George Church is professor of genetics at Harvard medical school and also heads the Lipper Center for Computational Genetics, MIT-Harvard/ Department of Energy Genomes to Life Center, and the National Institutes of Health (NIH) Center for Excellence in Genomic Science. Church’s Harvard lab is a member of the genome-sequencing technology development project of the NIH-National Human Genome Research Institute.

He’s also the inspiration behind a number of companies including Genome Therapeutics (since 1989), the sequencing part of which merged with Agencourt Biosciences in 2003, arguably the largest current-generation gene-sequencing company (recently acquired by Beckman Coulter for more than $100 million (depending on earn-outs) and a 2005 spin-off called Agencourt Personal Genomics. He has also contributed ideas to Codon Devices, a “synthetic biology” company that constructs large-scale integrated genetic circuits for anything from pharmaceutical manufacturing to biosensors and smart materials; Codon has funding from Kleiner Perkins (including Vinod Khosla personally) as well as Flagship and Alloy.

Most recently, Church led Harvard’s research project to design a faster and therefore cheaper way to sequence genomes, reported August 4 in the journal Science.. This followed by four days an announcement by company 454 Life Sciences, based in Branford, CT, of a similar achievement.

**Three magnitudes down, two more to go **Both groups have automated and miniaturized the process, which makes it much cheaper, faster and more accurate. The very first human genome sequence took 13 years and cost $2.7 billion (though the second was much quicker!). The current cost – if someone wanted it – would be about $20 million, or the price of Dennis Tito’s trip into space. Church’s and 454’s separate but similar approaches drop the cost to about $2 million. Their ultimate goal is about $1000, though Church points out that even $20,000 would be compatible with our current medical system: not for everyone, but akin to a complex operation.

But 454 sells its equipment for $500,000, whereas Church’s group is aiming for a more “community-oriented” effort. Church expects his approach to be used by 454’s three major competitors (including Agencourt) and, indeed, labs all around the world. In fact, he says “You can use equipment that’s currently available in most labs, for about $150,000, starting with a digital camera and a microscope; everyone has those. “The science paper includes step-by-step instructions, although they may not be for “anybody”: The final words of the paper are: "We collected ~786 gigabits of image data from which we gleaned only ~60 megabits of sequence. This sparsity - one useful bit of information per 10,000 bits collected - is a ripe avenue for improvement. The natural limit of this direction is single-pixel sequencing, in which the commonplace analogy between bytes and bases will be at its most manifest."

“I like commerce,” says Church, who is loosely connected with some 20 companies as an advisor or scientific contributor (as well as more closely with Agencourt and Codon). “But here, commercially, we’re going to race to the bottom. We’ll run workshops and do everything we can to spread the technology. Agencourt may want to become Amazon or eBay and do useful applications, not make money on the "browser", which spreads freely academically. We wrote the paper to make it extremely enabling. It’s a total cookbook: where to order the parts, how to use them…the opposite of how a commercial entity would write a paper.”

He describes the process, which can use tissues as simple as blood or swabs from a mouth: The material is immobilized into beads on a slide, while various solutions flow through it slowly. The system works basically by matching fragments from the sample onto a reference genome. That is, you can’t do the first instance of any species’ genome this way. You have to start with the multi-million-dollar model. But after that, it’s more like checking a new document against a reference copy for subtle changes, or fitting complementary pieces onto a long jigsaw puzzle. “I’m mostly a scientist, but when I touch engineering I get this rush of excitement,“ says Church. “You have to ignore all the things you can’t do, and not beat yourself up over what you could have done long ago. It’s so arbitrary, but so wonderful when you just make something work!”

Open-source medicine But Church isn’t content merely to create the technology; he understands that some people don’t want their genomes sequenced, and many more don’t want to share their information. “I see privacy attitudes in three buckets,” he says. “Some people want total privacy; they might not even want to know the information themselves. In the middle, people want just you and your own health-care provider to see it. And on the other end, a large group of researchers c

Satan's Castle.

"NBC Universal is one of the world's leading media and entertainment companies in the development, production, and marketing of entertainment, news, and information to a global audience. Formed in May 2004 through the combining of NBC and Vivendi Universal Entertainment, NBC Universal owns and operates a valuable portfolio of news and entertainment networks, a premier motion picture company, significant television production operations, a leading television stations group, and world-renowned theme parks. NBC Universal is 80% owned by General Electric and 20% owned by Vivendi."

From Corpwatch.org:

"Run until 2001by “Neutron” Jack Welch, who made it a matter of principle to lay off 10% of his workers per year, the world’s biggest company churns out plastics, aircraft engines and nuclear reactors and media spin through NBC, CNBC, Telemundo, and msnbc.com.

The world’s largest company by market share, General Electric’s revenues in 2003 totaled $134.2 billion. GE was run until 2001 by “Neutron” Jack Welch, who made it a matter of principle to lay off 10% of his workers per year.

General Electric is one of the world’s top three producers of jet engines, supplying Boeing, Lockheed Martin and other military aircraft makers for the powering of airplanes and helicopters.

The “war on terrorism” has seen GE’s military contracts rise substantially. But the company’s “defense” side has been doing well for a while. GE and other military contractors got a big boost under the Clinton administration from Presidential Directive 41 which stated that it was the job of US diplomats to promote arms sales abroad in order to safeguard American jobs; this directive tied the promotions of diplomats to how effectively they hocked US armaments."